Vical Inc. (VICL) Cut to “Hold” at Zacks Investment Research
Vical Inc. (NASDAQ:VICL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
Separately, HC Wainwright restated a “buy” rating and set a $8.00 price objective (down previously from $11.00) on shares of Vical in a report on Thursday, September 22nd.
Shares of Vical (NASDAQ:VICL) traded down 0.33% during midday trading on Wednesday, reaching $3.00. The company had a trading volume of 834 shares. The firm’s market capitalization is $27.62 million. Vical has a 12-month low of $2.80 and a 12-month high of $5.40. The company has a 50 day moving average of $3.48 and a 200 day moving average of $3.99.
Vical (NASDAQ:VICL) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.14. Vical had a negative return on equity of 14.18% and a negative net margin of 30.81%. The company earned $4.10 million during the quarter, compared to analysts’ expectations of $4.50 million. Analysts anticipate that Vical will post ($0.86) EPS for the current year.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors raised its stake in shares of Vical by 32.5% in the second quarter. BlackRock Fund Advisors now owns 23,459 shares of the company’s stock worth $106,000 after buying an additional 5,750 shares during the period. Eagle Global Advisors LLC purchased a new stake in shares of Vical during the second quarter worth $178,000. ClariVest Asset Management LLC purchased a new stake in shares of Vical during the second quarter worth $208,000. Finally, Renaissance Technologies LLC raised its stake in shares of Vical by 29.8% in the first quarter. Renaissance Technologies LLC now owns 2,073,599 shares of the company’s stock worth $811,000 after buying an additional 476,499 shares during the period. Institutional investors own 31.48% of the company’s stock.
Vical Company Profile
Receive News & Stock Ratings for Vical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Inc. and related stocks with our FREE daily email newsletter.